Meta-analysis of Indobufen Combined With Clopidogrel in the Treatment of Ischemic Stroke Patients.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY

Clinical Neuropharmacology Pub Date : 2025-06-13 DOI:10.1097/WNF.0000000000000642

Weiwei Yuan, Yan Shao

{"title":"Meta-analysis of Indobufen Combined With Clopidogrel in the Treatment of Ischemic Stroke Patients.","authors":"Weiwei Yuan, Yan Shao","doi":"10.1097/WNF.0000000000000642","DOIUrl":null,"url":null,"abstract":"Objectives: Currently, there is a paucity of optimal treatment method for ischemic stroke. This study conducted a meta-analysis of the application value of indobufen combined with clopidogrel in the field of ischemic stroke.Methods: The randomized controlled trials of indobufen combined with/without clopidogrel for the treatment of ischemic stroke were retrieved in Cochrane Library, PubMed, and CNKI from the establishment time of database to November 28, 2023. Cochrane risk-of-bias tool and Review Manager software were used for study quality evaluation and meta-analysis, respectively.Results: A total of 5 studies were ultimately included, published from 2021 to 2023, with a total of 408 patients. The meta-analysis results showed that the intervention group had a higher effective rate in treating stroke than the control group, with statistically significant difference (94.25% vs 75.29%, relative risk = 1.25, 95% confidence interval [CI] [1.14, 1.37], P < 0.00001), and there was no significant heterogeneity among the studies (P = 0.64, I2 = 0%). In addition, the meta-analysis results indicated that indobufen combined with clopidogrel decreased National Institutes of Health Stroke Scale score (mean difference [MD] = -3.52, 95% CI [-5.7, -1.35], P = 0.001), fibrinogen (MD = -0.65, 95% CI [-1.1, -0.2], P = 0.004), platelet aggregation (MD = -5.84, 95% CI [-6.96, -4.73], P < 0.00001), whole blood low shear viscosity (MD = -4.38, 95% CI [-4.81, -3.94], P < 0.00001), and whole blood high shear viscosity (MD = -0.96, 95% CI [-1.19, -0.73], P < 0.00001) and elevated thrombin time (MD = 0.42, 95% CI [0.09, 0.74], P = 0.01), but had no statistical effects on activated partial thromboplastin time and adverse reactions.Conclusion: The dual antiplatelet therapy regimen using indobufen and clopidogrel is suitable for the treatment of ischemic stroke, which can effectively alleviate neurological damage and inhibit cerebral thrombogenesis.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000642","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Currently, there is a paucity of optimal treatment method for ischemic stroke. This study conducted a meta-analysis of the application value of indobufen combined with clopidogrel in the field of ischemic stroke.

Methods: The randomized controlled trials of indobufen combined with/without clopidogrel for the treatment of ischemic stroke were retrieved in Cochrane Library, PubMed, and CNKI from the establishment time of database to November 28, 2023. Cochrane risk-of-bias tool and Review Manager software were used for study quality evaluation and meta-analysis, respectively.

Results: A total of 5 studies were ultimately included, published from 2021 to 2023, with a total of 408 patients. The meta-analysis results showed that the intervention group had a higher effective rate in treating stroke than the control group, with statistically significant difference (94.25% vs 75.29%, relative risk = 1.25, 95% confidence interval [CI] [1.14, 1.37], P < 0.00001), and there was no significant heterogeneity among the studies (P = 0.64, I2 = 0%). In addition, the meta-analysis results indicated that indobufen combined with clopidogrel decreased National Institutes of Health Stroke Scale score (mean difference [MD] = -3.52, 95% CI [-5.7, -1.35], P = 0.001), fibrinogen (MD = -0.65, 95% CI [-1.1, -0.2], P = 0.004), platelet aggregation (MD = -5.84, 95% CI [-6.96, -4.73], P < 0.00001), whole blood low shear viscosity (MD = -4.38, 95% CI [-4.81, -3.94], P < 0.00001), and whole blood high shear viscosity (MD = -0.96, 95% CI [-1.19, -0.73], P < 0.00001) and elevated thrombin time (MD = 0.42, 95% CI [0.09, 0.74], P = 0.01), but had no statistical effects on activated partial thromboplastin time and adverse reactions.

Conclusion: The dual antiplatelet therapy regimen using indobufen and clopidogrel is suitable for the treatment of ischemic stroke, which can effectively alleviate neurological damage and inhibit cerebral thrombogenesis.

查看原文本刊更多论文

吲哚布芬联合氯吡格雷治疗缺血性脑卒中的meta分析。

目的：目前，缺血性脑卒中的最佳治疗方法缺乏。本研究对吲哚布芬联合氯吡格雷在缺血性脑卒中领域的应用价值进行meta分析。方法：检索Cochrane Library、PubMed、中国知网自建库时间至2023年11月28日的吲哚布芬联用/不联用氯吡格雷治疗缺血性脑卒中的随机对照试验。分别使用Cochrane风险偏倚工具和Review Manager软件进行研究质量评价和meta分析。结果：最终共纳入5项研究，发表时间为2021 - 2023年，共408例患者。meta分析结果显示，干预组治疗脑卒中的有效率高于对照组，差异有统计学意义（94.25% vs 75.29%，相对危险度= 1.25,95%可信区间[CI] [1.14, 1.37], P < 0.00001），且研究间无显著异质性（P = 0.64, I2 = 0%）。此外,分析结果表明,indobufen结合氯吡格雷降低美国国立卫生研究院的中风尺度分数(平均差(MD) = -3.52, 95%可信区间[-5.7,-1.35],P = 0.001),纤维蛋白原(MD = -0.65, 95% CI [-1.1, -0.2], P = 0.004),血小板聚集(MD = -5.84, 95% CI [-6.96, -4.73], P < 0.00001),全血低剪切粘度(MD = -4.38, 95% CI [-4.81, -3.94], P < 0.00001),全血高剪切粘度(MD = -0.96, 95% CI [-1.19, -0.73],P < 0.00001)和凝血酶时间升高（MD = 0.42, 95% CI [0.09, 0.74], P = 0.01），但对活化部分凝血活酶时间和不良反应无统计学影响。结论：吲哚布芬与氯吡格雷联合抗血小板治疗方案适用于缺血性脑卒中，可有效减轻神经损伤，抑制脑血栓形成。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.